Is procalcitonin a good marker for Acinetobacter infections?

Year 2021, , 1 - 4, 22.01.2021

Zuhal Ozer Simsek

https://doi.org/10.38053/acmj.865035

Cited By: 1

Abstract

Aim: Culture is the most important method in the diagnosis of infectious diseases, but with the results of culture, the diagnosis can be made late. Therefore proinflammatory markers are used for early diagnosis of infections. Procalcitonin (PCT), a precursor of calcitonin, takes part in the systemic reaction caused by circulating endotoxins and inflammatory cytokines. The aim of this study was to investigate the potential usefulness of PCT in the acinetobacter or non-acinetobacter related infection diseases. Material and Method: In this study, 63 patients with Acinetobacter spp. and 33 patients with infections due to other bacterial agents were included. Leukocyte count, C-reactive protein (CRP) and PCT were used as inflammation markers. Findings / Results: In terms of PCT value between two groups, there was a statistically significant difference. The non - acinetobacter group had higher PCT levels than acinetobacter group. CRP and White blood cell (WBC) levels were not statistically significant difference between two groups. Conclusion: According to this study PCT may be not a useful marker for acinetobacter infections as early predictive value.

Keywords

Acinetobacter, procalcitonin, C-reactive protein, sepsis

References

• Peters RP, van Agtmael MA, Danner SA, Savelkoul PH, Vandenbroucke-Grauls CM. New developments in the diagnosis of bloodstream infections. Lancet Infect Dis 2004; 4: 751-60.
• Garnacho-Montero J, Huici-Moreno MJ, Gutierrez-Pizarraya A, et al. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Crit Care 2014; 18: R116.
• Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48: 2325-9.
• Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605-8.
• Fabre V, Sharara SL, Salinas AB, Carroll KC, Desai S, Cosgrove SE. Does this patient need blood cultures? a scoping review of indications for blood cultures in adult nonneutropenic inpatients. Clin Infect Dis 2020; 71: 1339-47.
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63: e61-e111.
• Moya F, Nieto A, JL RC. Calcitonin biosynthesis:evidence for a precursor. Eur J Biochem 1975; 55: 407-13.
• Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014; 34: 263-73.
• Hamade B, Huang DT. Procalcitonin: where are we now? Crit Care Clin 2020; 36: 23-40.
• Choe EA, Shin TG, Jo IJ, et al. The prevalence and clinical significance of low procalcitonin levels among patients with severe sepsis or septic shock in the emergency department. Shock 2016; 46: 37-43.
• Brodska H, Malickova K, Adamkova V, Benakova H, Stastna MM, Zima T. Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis. Clin Exp Med 2013; 13: 165-70.
• Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-8.
• Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock–a systematic review and meta-analysis. Critical Care 2013; 17: R291.
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia:2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63: e61-e111.
• Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011; 9: 107.
• de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients:a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16: 819-27.